Volume 27, Number 7—July 2021
Research
Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1
Maria L. Morales, Melinda B. Tanabe, A. Clinton White, Martha Lopez, Ruben Bascope, and Miguel M. Cabada
Table 2
Triclabendazole treatment outcomes per round for study of triclabendazole treatment failure for Fasciola hepatica infection for 146 preschool and school-age children, Cusco, Peru
| Round | Regimen, no. doses | Parasitologic cure, no. (%) | Parasitologic failure, no. (%) |
|---|---|---|---|
| 1 | 1 | 75 (54) | 64 (46) |
| 2 | 5 (71) | 2 (29) | |
| Overall |
80/146 (55) |
66/146 (45) |
|
| 2 | 1 | 5 (46) | 6 (55) |
| 2 | 17 (37) | 29 (63) | |
| >2 | 1 (33) | 2 (67) | |
| Overall |
23/60 (38) |
37/60 (62) |
|
| 3 | 1 | 0 (0) | 3 (100) |
| 2 | 2 (67) | 1 (33) | |
| >2 | 8 (30) | 19 (70) | |
| Overall |
10/33 (30) |
23/33 (70) |
|
| 4 | 2 | 0 (0) | 3 (100) |
| >2 | 5 (26) | 14 (74) | |
| Overall | 5/22 (22.7) | 17/22 (77.3) |
1Preliminary results from this study were presented at the 68th Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 20‒24, 2019, National Harbor, MD, USA.
Page created: April 26, 2021
Page updated: June 16, 2021
Page reviewed: June 16, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.